Intercept scores a mixed win on NASH Phase III sweepstakes, plans marketing pitch
Intercept Pharmaceuticals says they’ve cleared one of the high bars on their Phase III NASH study of obeticholic acid (OCA), setting up a pioneering marketing pitch in the coming months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
